The course, scheduled online on 14-16 June, is aimed to hematologists, pathologists and cytogeneticists and focuses on the study of hematological neoplasms.

The Josep Carreras Leukaemia Research Institute welcomes Expressions of Interest from excellent postdoctoral researchers to apply jointly with a research supervisor from Josep Carreras Institute to the European Commission Marie Sklodowska-Curie Postdoctoral Fellowship call (MSCA-PF-2022).

A team led by Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, has improved the computational identification of potentially druggable gene amplifications in tumors, from epigenetic data. By using this new tool, scientists can have reliable information on the molecular data of a particular tumor, both at the genetics and epigenetics level, even from scarce samples.

Open to the scientific community, this year Spetses Summer School will cover the topics of chromatin structure, epigenetic regulation, single-cell omics, and disease applications with a particular focus on cancer and leukaemia.

The Josep Carreras Institute becomes part of the Cancer Proteome project, an international initiative for the study of malignant tumors. It has the support of the Spanish Ministry of Science and Innovation, whose Minister, Diana Morant, visited the Josep Carreras Institute on Thursday and announced a grant of one million euros to promote the project.

The first trial with a CAR-T immunotherapy drug produced in Sant Pau, a pioneer in Europe, for the treatment of classic Hodgkin's lymphoma and non-Hodgkin T lymphoma CD30 + in relapse or refractory, has successfully completed its Phase I . The project is led by Dr. Javier Briones, Head of the Clinical Hematology Unit of the Hematology Service of the Hospital de Sant Pau and Head of the Cell Immunotherapy and Gene Therapy Research Group of the Research Institute of the Hospital de Sant Pau - IIB-Sant Pau and the Josep Carreras Leukaemia Research Institute.

The researchers team led by Dr. Marta Palomo, from the Josep Carreras Leukaemia Research Institute, and Dr. Fàtima Crispi, from BCNatal-IDIBAPS, has identified indicators which allow to differentiate both pathologies. In the framework of a project funded by the telethon Fundació La Marató of TV3, the outcome of this study opens the door to a more accurate diagnosis for both diseases and a better risk assessment. 

The diagnostic tools for leukemia that basic research makes available to clinicians are constantly increasing and new genomic sequencing and artificial intelligence technologies are penetrating a world dominated, until recently, by classical methodologies based on direct microscopic observation and analytical indicators.

The Josep Carreras Leukaemia Research Institute has signed an agreement to position the Institute as a collaborating entity of the Federació Empresarial de Badalona with the aim of promoting services, creating synergies and being part of the local business fabric.

Researchers at the Josep Carreras Leukaemia Research Institute have summarized all the previous knowledge on immunotherapy to make it easier for clinicians to dive into it. Recent advances open the door to new approaches in cancer treatments.